Exhibit 1
JOINT FILING AGREEMENT
The undersigned agree that the statement on Schedule 13D with respect to the common stock, $0.0001 par value per share, of Oyster Point Pharma, Inc., a Delaware corporation, dated as of November 14, 2019, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
Dated: November 14, 2019
| INVOPPS IV US, L.P. | ||
| By: InvOpps GP IV, L.L.C., its general partner | ||
| By: | /s/ Sacha Lainovic | |
| Name: Sacha Lainovic | ||
| Title: Managing Member | ||
| INVOPPS IV, L.P. | ||
| By: InvOpps GP IV, L.L.C., its general partner | ||
| By: | /s/ Sacha Lainovic | |
| Name: Sacha Lainovic | ||
| Title: Managing Member | ||
| INVOPPS GP IV, L.L.C. | ||
| By: | /s/ Sacha Lainovic | |
| Name: Sacha Lainovic | ||
| Title: Managing Member | ||
| /s/ Sacha Lainovic | ||
| Sacha Lainovic | ||
[Joint Filing Agreement - Oyster Point Pharma, Inc.]